Aleglitazar
Chemical compound
From Wikipedia, the free encyclopedia
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]
| Names | |
|---|---|
| Preferred IUPAC name
(2S)-2-Methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid | |
| Other names
Ro-0728804, R-1439 | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.220.523 |
| KEGG | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C24H23NO5S | |
| Molar mass | 437.51 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
